0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Small Case Series |

Functional Use of Hyaluronic Acid Gel in Lower Eyelid Retraction FREE

Maryam Zamani, MD; Sri Thyagarajan, MRCOphth, BS; Jane M. Olver, FRCS, FRCOphth
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2008;126(8):1157-1159. doi:10.1001/archopht.126.8.1157.
Text Size: A A A
Published online

Hyaluronic acid gel is a nonanimal, naturally occurring polysaccharide found in the extracellular matrix of connective tissue and is well suited as a soft-tissue filler in cosmetic surgery. Cross-linked hyaluronic acid gel is identical in composition across species with a low risk of allergic reaction.1It is a transparent, viscous, injectable tissue filler that can be found in varying particle sizes and whose effect lasts up to 9 months.2Lower eyelid retraction with exposure keratopathy and lagophthalmos is a challenging clinical problem. While symptoms of corneal exposure can be medically managed, traditional long-term treatments generally involve surgical intervention. We used hyaluronic acid gel as a minimally invasive nonsurgical alternative to treat secondary lower eyelid retraction causing corneal exposure and keratopathy in 5 patients with varying etiologies. This treatment formed part of the patients' clinical management and did not require institutional review board approval.

REPORT OF CASES

Injection location and volume were determined in the preoperative visit. Preinjection and postinjection photographs were taken with standard position and lighting by the same surgeon with a Nikon Coolpix 990 camera (Nikon, Melville, New York). Each injection was done by the same surgeon under local topical anesthetic using a 23-gauge and one-quarter–inch needle. We injected 0.2 to 2.0 mL of hyaluronic acid gel anterior to the orbital rim in the preperiosteal plane deep to the orbicularis oculi muscle to avoid visible irregular deposition and discoloration from the filler. Small amounts of hyaluronic acid gel were delivered via multiple injections, each in a threadlike manner with constant pressure to create volume (Figure 1). We aimed to inject a larger amount of hyaluronic acid gel posterior to the orbicularis oculi muscle to obtain a more marked functional use in 5 consecutive patients with secondary lower eyelid retraction. After the injection, the area was gently massaged to smooth any areas of irregularity. The patient was discharged after desirable filling of the contour and lid height were achieved. There were no postinjection instructions or restrictions.

Place holder to copy figure label and caption
Figure 1.

Photographs demonstrate the needle direction and positions used to inject hyaluronic acid gel anterior to the orbital rim in the preperiosteal plane deep to the orbicularis oculi muscle.

Graphic Jump Location

Photographic documentation of each patient preinjection and postinjection was used to calculate the change in inferior scleral show. Using Adobe Photoshop version CS2 (Adobe, San Jose, California), the distance of the lower lid margin to the inferior corneal limbus was compared with the horizontal corneal diameter of the same patient. Actual scleral show measurements were calculated in millimeters based on the assumption that the horizontal corneal diameter was 11.5 mm.

Eight lower eyelids (4 right and 4 left) of 5 patients (2 men, 3 women; average age of 56 years) were injected. Causes of lower eyelid retraction included lower eyelid blepharoplasty (4 patients) and lower motor neuron facial palsy (1 patient). All patients had undergone other periorbital and/or orbital surgeries and complained of symptoms associated with exposure keratopathy, including discomfort, foreign body sensation, and corneal keratopathy.

The average volume of hyaluronic acid gel used was 0.925 mL in the right lower eyelid and 0.824 mL in the left lower eyelid. This volume was tailored to the individual and based on clinical need. Four patients received Restylane (Q-Med AB, Uppsala, Sweden) and 1 patient received Perlane (Q-Med AB).

Hyaluronic acid gel injections raised the height of the lower eyelids, improved eyelid closure, and reduced symptoms of exposure keratitis. Preinjection and postinjection images are presented in Figure 2. Postinjection images were taken at 2 to 3 months after injection with the exception of Figure 2D. The mean improvement as demonstrated by the change in inferior scleral show was 1.08 mm when pretreatment and posttreatment images were compared. Moreover, the symptoms associated with corneal exposure were subjectively improved in all patients. One patient had hyaluronidase administered to diminish the effect of the injected hyaluronic acid gel.

Place holder to copy figure label and caption
Figure 2.

Photographs show each patient preinjection (left) and postinjection (right). These were used to calculate the change in inferior scleral show. Red lines indicate the corneal distances and yellow lines indicate scleral show distances, and asterisks indicate where Restylane (Q-Med AB, Uppsala, Sweden) was injected.

Graphic Jump Location

COMMENT

This small study demonstrates the functional use of hyaluronic acid gel for patients with secondary lower eyelid retraction. Hyaluronic acid gel has few adverse reactions, which include pain, discoloration of the skin, asymmetry, contour irregularities, and erythema. These are often transient and localized. However, simple procedures, such as the injection of dermal fillers, have the potential to induce reactions including loss of vision from embolization or direct injury to the globe with the needle.3

Depth of injection is critical to good volume augmentation with aesthetic success. To prevent a lumpy result, larger particle fillers are generally injected in deeper planes of tissue. Patients with persistent fullness (improper volume) or superficial injection of the hyaluronic acid (improper placement of filler) can be locally injected with 10 to 20 units of hyaluronidase. The fullness or contour abnormality is reduced immediately and the action of hyaluronidase works rapidly for 24 hours.4

CONCLUSIONS

Hyaluronic acid gel is an effective, minimally invasive treatment for lower eyelid retraction. While follow-up was short-term in this study, the longevity of hyaluronic acid gel in these patients will vary in long-term follow-up. Patient satisfaction was high, with improvement of exposure symptoms. In the same way that botulinum toxin is used to lower the upper eyelid by temporary chemodenervation of the levator muscle, hyaluronic acid gel can raise the lower eyelid temporarily. This small case series illustrates the use of hyaluronic acid gel injection in the treatment of lower eyelid retraction and should be considered in patients where surgery is not desirable or whose underlying condition may evolve such that surgical intervention is not appropriate.

ARTICLE INFORMATION

Correspondence:Dr Olver, Oculoplastic and Orbital Service, The Western Eye Hospital, Marylebone Road, London NW1 5YE, England (janeolver@aol.com).

Financial Disclosure:None reported.

REFERENCES

McCracken  MSKhan  JAWulc  AE  et al.  Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients. Ophthal Plast Reconstr Surg 2006;22 (3) 188- 191
PubMed Link to Article
Johl  SSBurgett  RA Fermal filler agents: a practical review. Curr Opin Ophthalmol 2006;17 (5) 471- 479
PubMed Link to Article
Goldberg  RAFiaschetti  D Filling the periorbital hollows with hyaluronic acid get: initial experience with 244 injections. Ophthal Plast Reconstr Surg 2006;22 (5) 335- 343
PubMed Link to Article
Steinsapir  KDSteinsapir  SM Deep-fill hyaluronic acid for the temporary treatment of naso-jugal groove: a report of 303 consecutive treatments. Ophthal Plast Reconstr Surg 2006;22 (5) 344- 348
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Photographs demonstrate the needle direction and positions used to inject hyaluronic acid gel anterior to the orbital rim in the preperiosteal plane deep to the orbicularis oculi muscle.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Photographs show each patient preinjection (left) and postinjection (right). These were used to calculate the change in inferior scleral show. Red lines indicate the corneal distances and yellow lines indicate scleral show distances, and asterisks indicate where Restylane (Q-Med AB, Uppsala, Sweden) was injected.

Graphic Jump Location

Tables

References

McCracken  MSKhan  JAWulc  AE  et al.  Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients. Ophthal Plast Reconstr Surg 2006;22 (3) 188- 191
PubMed Link to Article
Johl  SSBurgett  RA Fermal filler agents: a practical review. Curr Opin Ophthalmol 2006;17 (5) 471- 479
PubMed Link to Article
Goldberg  RAFiaschetti  D Filling the periorbital hollows with hyaluronic acid get: initial experience with 244 injections. Ophthal Plast Reconstr Surg 2006;22 (5) 335- 343
PubMed Link to Article
Steinsapir  KDSteinsapir  SM Deep-fill hyaluronic acid for the temporary treatment of naso-jugal groove: a report of 303 consecutive treatments. Ophthal Plast Reconstr Surg 2006;22 (5) 344- 348
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,039 Views
4 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs